Pantoprazole Olikla (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazole Olikla, is a proton pump inhibitor presented as a solid dosage form for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults.

GNH USA supplies Pantoprazole Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole Olikla is a proton‑pump inhibitor that acts on the gastric acid secretion pathway. - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.

Pantoprazole Olikla is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Constipation: infrequent.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): requires immediate medical attention. - Clostridioides difficile infection: may present with severe diarrhea. - Low magnesium levels (hypomagnesemia): can cause muscle cramps or cardiac arrhythmia. - Bone fractures: associated with long‑term use. - Acute interstitial nephritis: renal inflammation requiring evaluation.

When prescribing Pantoprazole Olikla, consider the following precautions: - Assess renal function: dose adjustment may be needed in severe impairment. - Monitor magnesium: long‑term therapy can lead to hypomagnesemia. - Evaluate bone health: prolonged use may increase fracture risk. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole Olikla may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption. - Atazanavir: decreased antiviral exposure. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: altered serum concentrations. - Methotrexate (high dose): reduced renal clearance. - Mycophenolate mofetil: decreased exposure. - Iron supplements: decreased iron absorption.